JP2012517427A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012517427A5 JP2012517427A5 JP2011549167A JP2011549167A JP2012517427A5 JP 2012517427 A5 JP2012517427 A5 JP 2012517427A5 JP 2011549167 A JP2011549167 A JP 2011549167A JP 2011549167 A JP2011549167 A JP 2011549167A JP 2012517427 A5 JP2012517427 A5 JP 2012517427A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- lung cancer
- cell type
- azacytidine
- small cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15147909P | 2009-02-10 | 2009-02-10 | |
| US61/151,479 | 2009-02-10 | ||
| PCT/US2010/000361 WO2010093435A1 (en) | 2009-02-10 | 2010-02-09 | Methods for treating non-small cell lung cancer using 5-azacytidine |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015032530A Division JP2015131822A (ja) | 2009-02-10 | 2015-02-23 | ５−アザシチジンを用いる、非小細胞肺癌の治療方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012517427A JP2012517427A (ja) | 2012-08-02 |
| JP2012517427A5 true JP2012517427A5 (OSRAM) | 2013-03-21 |
| JP6063628B2 JP6063628B2 (ja) | 2017-01-18 |
Family
ID=42115561
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011549167A Active JP6063628B2 (ja) | 2009-02-10 | 2010-02-09 | ５−アザシチジンを用いる、非小細胞肺癌の治療方法 |
| JP2015032530A Pending JP2015131822A (ja) | 2009-02-10 | 2015-02-23 | ５−アザシチジンを用いる、非小細胞肺癌の治療方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015032530A Pending JP2015131822A (ja) | 2009-02-10 | 2015-02-23 | ５−アザシチジンを用いる、非小細胞肺癌の治療方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US8492361B2 (OSRAM) |
| EP (1) | EP2396007A1 (OSRAM) |
| JP (2) | JP6063628B2 (OSRAM) |
| CA (1) | CA2789365A1 (OSRAM) |
| WO (1) | WO2010093435A1 (OSRAM) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010093435A1 (en) | 2009-02-10 | 2010-08-19 | Celgene International Sarl | Methods for treating non-small cell lung cancer using 5-azacytidine |
| WO2013022872A1 (en) | 2011-08-10 | 2013-02-14 | Celgene Corporation | Gene methylation biomarkers and methods of use thereof |
| HK1200354A1 (en) | 2011-09-26 | 2015-08-07 | 细胞基因公司 | Combination therapy for chemoresistant cancers |
| HK1200716A1 (zh) | 2011-11-01 | 2015-08-14 | 细胞基因公司 | 使用胞苷類似物的口服製劑治療癌症的方法 |
| NZ628410A (en) | 2012-02-24 | 2016-03-31 | Signal Pharm Llc | Methods for treating non-small cell lung cancer using tor kinase inhibitor combination therapy |
| MX374749B (es) * | 2013-04-17 | 2025-03-06 | Signal Pharm Llc | Terapia de combinacion que comprende un inhibidor de tor cinasa y un analogo de citidina para tratar cancer. |
| WO2014180996A1 (en) * | 2013-05-10 | 2014-11-13 | Embl | Use of 5-azacytidine to inhibit nonsense-mediated rna decay (nmd) |
| CA2946538A1 (en) | 2014-04-04 | 2015-10-08 | Del Mar Pharmaceuticals | Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer |
| WO2015160868A1 (en) | 2014-04-16 | 2015-10-22 | Signal Pharmaceuticals, Llc | Methods for treating cancer using tor kinase inhibitor combination therapy |
| WO2015160882A1 (en) | 2014-04-16 | 2015-10-22 | Signal Pharmaceuticals, Llc | SOLID FORMS COMPRISING 7-(6-(2-HYDROXYPROPAN-2YL) PYRIDIN-3-YL)-1-(TRANS)-4-METHOXYCYCLOHEXYL)-3, 4-DIHYDROPYRAZINO[2,3-b] PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF |
| WO2015195786A2 (en) * | 2014-06-17 | 2015-12-23 | Celgene Corporation | Methods for treating cancers using oral formulations of cytidine analogs |
| CA2960490A1 (en) * | 2014-09-08 | 2016-03-17 | Celgene Corporation | Methods for treating a disease or disorder using oral formulations of cytidine analogs in combination with an anti-pd1 or anti-pdl1 monoclonal antibody |
| US9801983B2 (en) | 2014-12-18 | 2017-10-31 | Cook Medical Technologies Llc | Medical devices for delivering a bioactive to a point of treatment and methods of making medical devices |
| WO2016201337A1 (en) * | 2015-06-12 | 2016-12-15 | Immungene, Inc. | Engineered antibody-interferon fusion molecules for the treatment of glucose-regulated protein 94 (grp94) expressing cancers |
| DK3960182T3 (da) | 2015-12-03 | 2025-04-07 | Epidestiny Inc | Sammensætninger indeholdende decitabin, 5-azacytidin og tetrahydrouridin samt anvendelser deraf |
| MY198676A (en) | 2017-06-22 | 2023-09-15 | Celgene Corp | Treatment of hepatocellular carcinoma characterized by hepatitis b virus infection |
| EP3749298B1 (en) * | 2018-02-07 | 2023-04-05 | Lovelace Biomedical Research Institute | Inhalable dry powder cytidine analogue composition and method of use as a treatment for cancer |
| KR102785135B1 (ko) | 2018-06-11 | 2025-03-21 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 눈 질환을 치료하는 탈메틸화 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060063735A1 (en) * | 2004-09-17 | 2006-03-23 | Supergen, Inc. | Salts of 5-azacytidine |
| CA2742252A1 (en) | 2007-11-01 | 2009-05-07 | Celgene Corporation | Cytidine analogs for treatment of myelodysplastic syndromes |
| AU2009246926B2 (en) | 2008-05-15 | 2014-06-26 | Celgene Corporation | Oral formulations of cytidine analogs and methods of use thereof |
| WO2010093435A1 (en) | 2009-02-10 | 2010-08-19 | Celgene International Sarl | Methods for treating non-small cell lung cancer using 5-azacytidine |
| WO2013022872A1 (en) | 2011-08-10 | 2013-02-14 | Celgene Corporation | Gene methylation biomarkers and methods of use thereof |
-
2010
- 2010-02-09 WO PCT/US2010/000361 patent/WO2010093435A1/en not_active Ceased
- 2010-02-09 EP EP10704434A patent/EP2396007A1/en not_active Withdrawn
- 2010-02-09 JP JP2011549167A patent/JP6063628B2/ja active Active
- 2010-02-09 US US13/148,636 patent/US8492361B2/en active Active
- 2010-02-09 CA CA2789365A patent/CA2789365A1/en not_active Abandoned
-
2013
- 2013-06-07 US US13/913,248 patent/US8841277B2/en not_active Expired - Fee Related
-
2015
- 2015-02-23 JP JP2015032530A patent/JP2015131822A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012517427A5 (OSRAM) | ||
| Wu et al. | Asiatic acid inhibits lung cancer cell growth in vitro and in vivo by destroying mitochondria | |
| KR101884960B1 (ko) | 체크포인트 키나제 1 억제제 및 wee 1 키나제 억제제의 조합 | |
| Karp et al. | Sequential flavopiridol, cytosine arabinoside, and mitoxantrone: a phase II trial in adults with poor-risk acute myelogenous leukemia | |
| Knobloch et al. | Suppression of proinflammatory and prosurvival biomarkers in oral cancer patients consuming a black raspberry phytochemical-rich troche | |
| JP2014532704A5 (OSRAM) | ||
| EP2416773B1 (en) | Checkpoint kinase 1 inhibitors for potentiating dna damaging agents | |
| Temkin et al. | A phase I study of weekly temsirolimus and topotecan in the treatment of advanced and/or recurrent gynecologic malignancies | |
| KR20170084034A (ko) | 암 치료용 의약 조성물 제조에서의 아젤니디핀의 용도 | |
| JP2012526850A5 (OSRAM) | ||
| HK1206246A1 (en) | Use of high dose laquinimod for treating multiple sclerosis | |
| HRP20250902T1 (hr) | Liječenje raka pluća korištenjem kombinacije anti‑pd‑1 antitijela i anti‑ctla‑4 antitijela | |
| Ran et al. | Successful treatment of oral itraconazole for infantile hemangiomas: a case series | |
| Ren et al. | Epigenetic interventions increase the radiation sensitivity of cancer cells | |
| JP2016529285A5 (OSRAM) | ||
| JP2014504636A5 (OSRAM) | ||
| JP2010527908A (ja) | Ｃｎｄａｃ（２’−シアノ−２’−デオキシ−ｎ４−パルミトイル−１−ベータ−ｄ−アラビノフラノシル−シトシン）及び細胞毒性薬を含む組合せ | |
| JP2012508239A5 (OSRAM) | ||
| KR102128866B1 (ko) | 오로라 키나제 저해제를 사용하는 암 치료 방법 | |
| ES3040063T3 (en) | Combination of a protein kinase inhibitor and an additional chemotherapeutic agent | |
| EA037667B1 (ru) | Лечение рака | |
| FI3919060T3 (fi) | Ecopipam touretten oireyhtymän hoitoon | |
| JP2011500650A5 (OSRAM) | ||
| JP2015524460A5 (OSRAM) | ||
| JP2016503063A5 (OSRAM) |